Thailand Diabetes Drugs And Devices Market Size (2024 - 2029)

The Thailand diabetes drugs and devices market is projected to experience growth over the forecast period, driven by various factors including the impact of COVID-19 on healthcare systems. The pandemic prompted the Thai government to implement innovative solutions such as telemedicine and home isolation programs to manage healthcare delivery, which have contributed to the expansion of diabetes management services. Additionally, the government's efforts in providing essential medical supplies and support for diabetes self-management are expected to further enhance the market's scale. These developments indicate a positive trajectory for the market size in the coming years.

Market Size of Thailand Diabetes Drugs And Devices Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Thailand Diabetes Drugs and Devices Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 0.28 Billion
Market Size (2029) USD 0.35 Billion
CAGR (2024 - 2029) 5.02 %

Major Players

Thailand Diabetes Drugs And Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Thailand Diabetes Drugs and Devices Market Analysis

The Thailand Diabetes Drugs And Devices Market size is estimated at USD 0.28 billion in 2024, and is expected to reach USD 0.35 billion by 2029, growing at a CAGR of greater than 5.02% during the forecast period (2024-2029).

Healthcare systems have been significantly disrupted and strained at every stage of the rapid spread of COVID-19. Several countries, notably the Thai government, have implemented home quarantine or home isolation programs to prevent medical collapse and improve inadequate medical resources. The number of people infected with COVID-19 in hospitals has increased. Previous studies have shown that telemedicine-based COVID-19 home monitoring programs are feasible in several countries to fill treatment gaps during health worker shortages. These programs monitored symptom intensity and informed patients to seek additional treatment if needed. During the COVID-19 epidemic, hospital capacity was insufficient, and a home isolation system was introduced.

The Thai government has launched education and support on Diabetes Self-Management (DSMES) and telemedicine glycemic control, along with outcomes for COVID-19 patients who have been quarantined at home. In August 2022, the National Research Council of Thailand (NRCT) unveiled a prototype of a Breathalyzer detector that can detect people infected with the new coronavirus with 97% accuracy.

The Thai government has provided medical supplies such as blood glucose meters, blood glucose test strips, lancets and urine test strips donated or purchased with donations during the COVID-19 crisis. Supplies were stored in a central location and distributed by volunteers using same-day commercial delivery services. Pre-filled disposable insulin pens, both long-acting and short-acting analogues, have been chosen instead of insulin vials to reduce dosing errors, especially in insulin patients. Insulin pens were stored at the clinic and distributed by same-day delivery service in temperature-controlled containers.

Thus, the above factors are expected to drive market growth over the forecast period.

Thailand Diabetes Drugs and Devices Industry Segmentation

Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. To control blood sugar levels, insulin must be given several times daily, such as when eating or drinking. Many people with type 2 diabetes also need to take antidiabetic drugs. These drugs include diabetes medications and injections such as insulin. Thailand's diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs) and devices (management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood and continuous glucose monitoring)). The report offers the value (in USD) and volume (in Unit) for the above segments.

Devices
Monitoring Devices
Self-monitoring Blood Glucose Devices
Continuous Blood Glucose Monitoring
Management Devices
Insulin Pump
Insulin Syringes
Insulin Cartridges
Disposable Pens
Drugs
Oral Anti-Diabetes Drugs
Insulin Drugs
Combination Drugs
Non-Insulin Injectable Drugs
Need A Different Region Or Segment?
Customize Now

Thailand Diabetes Drugs And Devices Market Size Summary

The Thailand diabetes drugs and devices market is poised for significant growth over the forecast period, driven by various factors including government initiatives and advancements in diabetes management technologies. The Thai government's efforts to enhance diabetes self-management education and telemedicine services, particularly during the COVID-19 pandemic, have played a crucial role in supporting patients and maintaining healthcare services. The introduction of innovative devices such as continuous glucose monitors, which provide real-time blood sugar level readings, is expected to further propel market expansion. These devices, along with government subsidies and support, are anticipated to make diabetes monitoring more accessible and affordable, thereby encouraging market players to explore opportunities in Thailand.

The increasing prevalence of diabetes in Thailand, attributed to lifestyle changes and urbanization, underscores the need for effective diabetes management solutions. The government's strategic health plans aim to combat the rising incidence of diabetes by promoting healthier lifestyles and improving awareness of diabetes devices. As diabetes care continues to represent a significant portion of healthcare expenditure, the market is expected to benefit from ongoing investments and partnerships among key industry players. Companies like Novo Nordisk and Abbott Diabetes Care are actively collaborating to enhance diabetes management through connected devices, while regulatory approvals for advanced insulin delivery systems, such as insulin pens, are facilitating better treatment options for patients.

Explore More

Thailand Diabetes Drugs And Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Dynamics

      1. 1.2.1 Market Drivers

      2. 1.2.2 Market Restraints

    3. 1.3 \Porter's Five Forces Analysis

      1. 1.3.1 Bargaining Power of Suppliers

      2. 1.3.2 Bargaining Power of Consumers

      3. 1.3.3 Threat of New Entrants

      4. 1.3.4 Threat of Substitute Products and Services

      5. 1.3.5 Intensity of Competitive Rivalry

  2. 2. Market Segmentation (Market Size by Value - USD)

    1. 2.1 Devices

      1. 2.1.1 Monitoring Devices

        1. 2.1.1.1 Self-monitoring Blood Glucose Devices

        2. 2.1.1.2 Continuous Blood Glucose Monitoring

      2. 2.1.2 Management Devices

        1. 2.1.2.1 Insulin Pump

        2. 2.1.2.2 Insulin Syringes

        3. 2.1.2.3 Insulin Cartridges

        4. 2.1.2.4 Disposable Pens

    2. 2.2 Drugs

      1. 2.2.1 Oral Anti-Diabetes Drugs

      2. 2.2.2 Insulin Drugs

      3. 2.2.3 Combination Drugs

      4. 2.2.4 Non-Insulin Injectable Drugs

Thailand Diabetes Drugs And Devices Market Size FAQs

The Thailand Diabetes Drugs And Devices Market size is expected to reach USD 0.28 billion in 2024 and grow at a CAGR of greater than 5.02% to reach USD 0.35 billion by 2029.

In 2024, the Thailand Diabetes Drugs And Devices Market size is expected to reach USD 0.28 billion.

Thailand Diabetes Drugs and Devices Market - Growth, Trends, Covid-19 Impact, and Forecasts (2024 - 2029)